US20040072735A1 - Methods of inducing terminal differentiation - Google Patents

Methods of inducing terminal differentiation Download PDF

Info

Publication number
US20040072735A1
US20040072735A1 US10/379,149 US37914903A US2004072735A1 US 20040072735 A1 US20040072735 A1 US 20040072735A1 US 37914903 A US37914903 A US 37914903A US 2004072735 A1 US2004072735 A1 US 2004072735A1
Authority
US
United States
Prior art keywords
subject
composition
saha
hdac inhibitor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/379,149
Other languages
English (en)
Inventor
Victoria Richon
Judy Chiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Merck HDAC Research LLC
Original Assignee
Richon Victoria M.
Chiao Judy H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040072735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richon Victoria M., Chiao Judy H. filed Critical Richon Victoria M.
Priority to NZ55018503A priority Critical patent/NZ550185A/xx
Priority to US10/379,149 priority patent/US20040072735A1/en
Priority to US10/600,132 priority patent/US7456219B2/en
Priority to US10/616,649 priority patent/US7399787B2/en
Priority to US10/650,025 priority patent/US7148257B2/en
Priority to US10/665,079 priority patent/US20040127523A1/en
Priority to US10/692,523 priority patent/US20040132825A1/en
Publication of US20040072735A1 publication Critical patent/US20040072735A1/en
Priority to US10/567,952 priority patent/US20070060614A1/en
Priority to US11/391,971 priority patent/US7375137B2/en
Priority to US11/492,478 priority patent/US20060276547A1/en
Assigned to MERCK HDAC RESEARCH, LLC reassignment MERCK HDAC RESEARCH, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATON PHARMA, INC.
Assigned to ATON PHARMA, INC. (A SUBSIDIARY OF MERCK & CO., INC.) reassignment ATON PHARMA, INC. (A SUBSIDIARY OF MERCK & CO., INC.) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHIAO, JUDY H., MILLER, THOMAS A., RICHON, VICTORIA M.
Assigned to SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH reassignment SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KELLY, W. KEVIN, RICHON, VICTORIA M.
Priority to US11/853,700 priority patent/US7732490B2/en
Priority to US11/981,367 priority patent/US7652069B2/en
Priority to US11/981,500 priority patent/US20080249179A1/en
Priority to US11/980,994 priority patent/US20080227862A1/en
Priority to US11/983,469 priority patent/US20080114069A1/en
Priority to US12/077,415 priority patent/US7847122B2/en
Priority to US12/077,396 priority patent/US7851509B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: SLOAN-KETTERING INSTITUTE FOR CANCER RES
Priority to US12/653,073 priority patent/US8101663B2/en
Priority to US12/799,368 priority patent/US8067472B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: SLOAN-KETTERING INSTITUTE FOR CANCER RES
Priority to US13/276,710 priority patent/US20120041067A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
US10/379,149 2002-03-04 2003-03-04 Methods of inducing terminal differentiation Abandoned US20040072735A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
NZ55018503A NZ550185A (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US10/379,149 US20040072735A1 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
US10/600,132 US7456219B2 (en) 2002-03-04 2003-06-19 Polymorphs of suberoylanilide hydroxamic acid
US10/616,649 US7399787B2 (en) 2002-03-04 2003-07-09 Methods of treating cancer with HDAC inhibitors
US10/650,025 US7148257B2 (en) 2002-03-04 2003-08-26 Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US10/665,079 US20040127523A1 (en) 2002-03-04 2003-09-16 Methods of treating cancer with HDAC inhibitors
US10/692,523 US20040132825A1 (en) 2002-03-04 2003-10-24 Methods of treating cancer with HDAC inhibitors
US10/567,952 US20070060614A1 (en) 2002-03-04 2004-08-26 Methods of treating cancer with hdac inhibitors
US11/391,971 US7375137B2 (en) 2002-03-04 2006-03-28 Methods of treating cancer with HDAC inhibitors
US11/492,478 US20060276547A1 (en) 2002-03-04 2006-07-24 Methods of treating cancer with HDAC inhibitors
US11/853,700 US7732490B2 (en) 2002-03-04 2007-09-11 Methods of treating cancer
US11/980,994 US20080227862A1 (en) 2002-03-04 2007-10-30 Methods of treating cancer with HDAC inhibitors
US11/981,367 US7652069B2 (en) 2002-03-04 2007-10-30 Polymorphs of suberoylanilide hydroxamic acid
US11/981,500 US20080249179A1 (en) 2002-03-04 2007-10-30 Methods of treating cancer with HDAC inhibitors
US11/983,469 US20080114069A1 (en) 2002-03-04 2007-11-09 Methods of inducing terminal differentiation
US12/077,396 US7851509B2 (en) 2002-03-04 2008-03-18 Polymorphs of suberoylanilide hydroxamic acid
US12/077,415 US7847122B2 (en) 2002-03-04 2008-03-18 Polymorphs of suberoylanilide hydroxamic acid
US12/653,073 US8101663B2 (en) 2002-03-04 2009-12-07 Polymorphs of suberoylanilide hydroxamic acid
US12/799,368 US8067472B2 (en) 2002-03-04 2010-04-23 Methods of treating Hodgkin's and non-Hodgkin's lymphoma
US13/276,710 US20120041067A1 (en) 2002-03-04 2011-10-19 Methods of Inducing Terminal Differentiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36175902P 2002-03-04 2002-03-04
US10/379,149 US20040072735A1 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US10/600,132 Continuation-In-Part US7456219B2 (en) 2002-03-04 2003-06-19 Polymorphs of suberoylanilide hydroxamic acid
US10/616,649 Continuation-In-Part US7399787B2 (en) 2002-03-04 2003-07-09 Methods of treating cancer with HDAC inhibitors
US10/650,025 Continuation-In-Part US7148257B2 (en) 2002-03-04 2003-08-26 Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US10/665,079 Continuation-In-Part US20040127523A1 (en) 2002-03-04 2003-09-16 Methods of treating cancer with HDAC inhibitors
US10/692,523 Continuation-In-Part US20040132825A1 (en) 2002-03-04 2003-10-24 Methods of treating cancer with HDAC inhibitors
US11/853,700 Continuation US7732490B2 (en) 2002-03-04 2007-09-11 Methods of treating cancer

Publications (1)

Publication Number Publication Date
US20040072735A1 true US20040072735A1 (en) 2004-04-15

Family

ID=27805074

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/379,149 Abandoned US20040072735A1 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation
US10/616,649 Active 2025-04-14 US7399787B2 (en) 2002-03-04 2003-07-09 Methods of treating cancer with HDAC inhibitors
US10/665,079 Abandoned US20040127523A1 (en) 2002-03-04 2003-09-16 Methods of treating cancer with HDAC inhibitors
US11/853,700 Active US7732490B2 (en) 2002-03-04 2007-09-11 Methods of treating cancer
US11/983,469 Abandoned US20080114069A1 (en) 2002-03-04 2007-11-09 Methods of inducing terminal differentiation
US12/799,368 Expired - Fee Related US8067472B2 (en) 2002-03-04 2010-04-23 Methods of treating Hodgkin's and non-Hodgkin's lymphoma
US13/276,710 Abandoned US20120041067A1 (en) 2002-03-04 2011-10-19 Methods of Inducing Terminal Differentiation

Family Applications After (6)

Application Number Title Priority Date Filing Date
US10/616,649 Active 2025-04-14 US7399787B2 (en) 2002-03-04 2003-07-09 Methods of treating cancer with HDAC inhibitors
US10/665,079 Abandoned US20040127523A1 (en) 2002-03-04 2003-09-16 Methods of treating cancer with HDAC inhibitors
US11/853,700 Active US7732490B2 (en) 2002-03-04 2007-09-11 Methods of treating cancer
US11/983,469 Abandoned US20080114069A1 (en) 2002-03-04 2007-11-09 Methods of inducing terminal differentiation
US12/799,368 Expired - Fee Related US8067472B2 (en) 2002-03-04 2010-04-23 Methods of treating Hodgkin's and non-Hodgkin's lymphoma
US13/276,710 Abandoned US20120041067A1 (en) 2002-03-04 2011-10-19 Methods of Inducing Terminal Differentiation

Country Status (18)

Country Link
US (7) US20040072735A1 (US20040072735A1-20040415-C00009.png)
EP (4) EP2082737B1 (US20040072735A1-20040415-C00009.png)
JP (4) JP4732693B2 (US20040072735A1-20040415-C00009.png)
KR (2) KR100892016B1 (US20040072735A1-20040415-C00009.png)
CN (3) CN103393630A (US20040072735A1-20040415-C00009.png)
AU (1) AU2003213684C1 (US20040072735A1-20040415-C00009.png)
BR (1) BR0308250A (US20040072735A1-20040415-C00009.png)
CA (3) CA2671976C (US20040072735A1-20040415-C00009.png)
ES (1) ES2532607T3 (US20040072735A1-20040415-C00009.png)
HK (1) HK1072362A1 (US20040072735A1-20040415-C00009.png)
IL (3) IL163909A0 (US20040072735A1-20040415-C00009.png)
MX (1) MXPA04008577A (US20040072735A1-20040415-C00009.png)
NO (2) NO329984B1 (US20040072735A1-20040415-C00009.png)
NZ (3) NZ567758A (US20040072735A1-20040415-C00009.png)
PL (1) PL372239A1 (US20040072735A1-20040415-C00009.png)
RU (3) RU2320331C2 (US20040072735A1-20040415-C00009.png)
WO (1) WO2003075839A2 (US20040072735A1-20040415-C00009.png)
ZA (2) ZA200407942B (US20040072735A1-20040415-C00009.png)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018968A1 (en) * 2002-04-15 2004-01-29 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US20040087631A1 (en) * 2002-03-04 2004-05-06 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid
US20040127523A1 (en) * 2002-03-04 2004-07-01 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040254220A1 (en) * 2003-03-17 2004-12-16 Syrrx, Inc. Histone deacetylase inhibitors
US20050048847A1 (en) * 2002-08-27 2005-03-03 Guang-Rung Hsieh Electrical power jack
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20060009526A1 (en) * 2002-02-15 2006-01-12 Richon Victoria M Method of treating TRX mediated diseases
US20060079551A1 (en) * 2001-10-16 2006-04-13 Richon Victoria M Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20060205941A1 (en) * 2004-12-16 2006-09-14 Bressi Jerome C Histone deacetylase inhibitors
US20060258694A1 (en) * 2005-05-11 2006-11-16 Bressi Jerome C Histone deacetylase inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070015809A1 (en) * 2005-07-14 2007-01-18 Bressi Jerome C Histone deacetylase inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
WO2007031853A2 (en) * 2005-09-14 2007-03-22 Nya Hamlet Pharma Ab Therapeutic combination of hamlet and a hdac inhibitor to treat cancer
WO2007056244A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
US20070173527A1 (en) * 2006-01-13 2007-07-26 Bressi Jerome C Histone deacetylase inhibitors
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
EP1833500A1 (en) * 2004-12-14 2007-09-19 Biorunx Co., Ltd Method to enhance the bone formation activity of bmp by runx2 acetylation
US20080124403A1 (en) * 2006-06-08 2008-05-29 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US20080132575A1 (en) * 2005-05-20 2008-06-05 Jeannie Chow Wong Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same
US20080194690A1 (en) * 2005-05-13 2008-08-14 Topotarget Uk Limited Pharmaceutical Formulations Of Hdac Inhibitors
US20080202944A1 (en) * 2005-04-22 2008-08-28 Eduardo Santoli Method for Use of an Electrochemical Sensor and Electrodes Forming Said Sensor
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
US20090012175A1 (en) * 2003-08-26 2009-01-08 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20090186382A1 (en) * 2006-12-29 2009-07-23 Verdine Gregory L Preparation of Romidepsin
US20090215800A1 (en) * 2005-05-05 2009-08-27 Chroma Therapeutics Ltd Enzyme and Receptor Modulation
US20090305956A1 (en) * 2006-04-24 2009-12-10 Gloucester Pharmaceuticals, Inc. Treatment of Ras-Expressing Tumors
US20100093610A1 (en) * 2006-12-29 2010-04-15 Vrolijk Nicholas H Romidepsin-based treatments for cancer
US20100113602A1 (en) * 2007-02-27 2010-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US20100113392A1 (en) * 2006-11-03 2010-05-06 Badros Ashraf Z Methods of using saha and bortezomib for treating multiple myeloma
US20100190694A1 (en) * 2009-01-14 2010-07-29 Jan Fagerberg Methods for identifying patients who will respond well to cancer treatment
US20100286279A1 (en) * 2007-09-25 2010-11-11 Topotarget Uk Limited Methods of Synthesis of Certain Hydroxamic Acid Compounds
US20100317678A1 (en) * 2006-10-30 2010-12-16 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US20110003777A1 (en) * 2008-03-07 2011-01-06 Topotarget A/S Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat
WO2012045804A1 (en) * 2010-10-08 2012-04-12 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US10285959B2 (en) 2005-02-03 2019-05-14 Topotarget Uk Limited Combination therapies using HDAC inhibitors
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
JP2006523693A (ja) * 2003-04-01 2006-10-19 メモリアル スローン−ケタリング キャンサー センター ヒドロキサム酸化合物およびその使用方法
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
KR20050022216A (ko) * 2003-08-25 2005-03-07 윤덕구 동결건조 즉석소면 및 그 제조방법
CA2576667A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
BRPI0606319A2 (pt) * 2005-01-21 2009-06-16 Astex Therapeutics Ltd compostos farmacêuticos
US20080161251A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
ES2552338T3 (es) * 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
CA2937005A1 (en) 2005-03-22 2006-09-28 President And Fellows Of Harvard College Treatment of protein degradation disorders
WO2006113606A2 (en) * 2005-04-18 2006-10-26 Johns Hopkins University Histone deacetylase inhibitors
EP2229941A1 (en) * 2005-05-20 2010-09-22 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
JP2009507081A (ja) * 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
EP1940379A4 (en) * 2005-09-30 2009-05-13 Jackson H M Found Military Med METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES
CA2626679C (en) * 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
NZ568471A (en) * 2005-12-05 2010-09-30 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
MX2008010462A (es) 2006-02-14 2009-04-17 Harvard College Inhibidores de histona desacetilasa.
CA2654540C (en) * 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US20100016435A1 (en) * 2006-05-16 2010-01-21 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
CA2663569A1 (en) * 2006-09-28 2008-04-03 Merck & Co., Inc. Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
AU2008341671B2 (en) * 2007-12-20 2012-07-26 Pharma Mar, S.A. Antitumoral compounds
CA2731730C (en) * 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
CN102264694B (zh) 2008-10-15 2015-11-25 基因里克斯(英国)有限公司 用于制备伏立诺他的方法
WO2010061219A2 (en) 2008-11-26 2010-06-03 Generics [Uk] Limited Polymorphs
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
ES2473792T3 (es) 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
WO2011056542A1 (en) 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US8293537B2 (en) * 2010-02-10 2012-10-23 Selinfreund Richard H Systems and methods for hemoglobin analysis
WO2011127467A1 (en) * 2010-04-09 2011-10-13 Companion Diagnostics, Inc. Devices, systems, and methods for biomarker stabilization
CA2798220A1 (en) 2010-05-05 2011-11-10 Teva Women's Health, Inc. Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
US20120164674A1 (en) * 2010-10-28 2012-06-28 Selinfreund Richard H Devices and washes for biomarker stabilization
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
CN102793693A (zh) * 2012-09-07 2012-11-28 天津医科大学 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
CN103819364B (zh) * 2014-01-24 2015-12-02 中南大学 N-烃酰基环内酰胺衍生物的一锅合成方法
AU2016209244A1 (en) 2015-01-23 2017-08-17 Helena M.G.P.V. Reis Use of short chain fatty acids in cancer prevention
WO2016164392A1 (en) 2015-04-06 2016-10-13 The Johns Hopkins University A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells
CN105055386A (zh) * 2015-08-12 2015-11-18 天津医科大学总医院 伏立诺他用于制备免疫调节药物的应用
CN106187818B (zh) * 2016-06-27 2017-12-08 刘美新 一种制备抗癌药物伏立诺他的方法
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
MX2022003490A (es) 2019-09-27 2022-04-25 Takeda Pharmaceuticals Co Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6).

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690918A (en) * 1985-01-30 1987-09-01 Teruhiko Beppu Use of trichostatin compounds for treating tumor cells
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5654333A (en) * 1991-10-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Methods for prevention of cancer using phenylacetic acids and derivatives thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6239176B1 (en) * 1997-03-11 2001-05-29 Beacon Laboratories, Inc. Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20030082666A1 (en) * 2000-11-21 2003-05-01 Kammer Gary M. Method of treating autoimmune diseases
US20030161830A1 (en) * 2001-06-14 2003-08-28 Jackson Donald G. Novel human histone deacetylases
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US20040087631A1 (en) * 2002-03-04 2004-05-06 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid
US20040127522A1 (en) * 2002-03-04 2004-07-01 Chiao Judy H. Methods of treating cancer with HDAC inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
US20040167184A1 (en) * 2001-03-27 2004-08-26 Wiech Norbert L. Treatment of lung cells with histone deacetylase inhibitors
US20040266818A1 (en) * 2003-04-01 2004-12-30 Ronald Breslow Hydroxamic acid compounds and methods of use thereof
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA622801A (en) 1961-06-27 L. Clark Robert Substituted benzimidazolones
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61251649A (ja) * 1985-04-05 1986-11-08 Mitsubishi Petrochem Co Ltd ジカルボン酸ジアニリドの製造法
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
EP0855024A4 (en) 1995-09-20 2001-08-22 Merck & Co Inc HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES
US6239178B1 (en) * 1996-05-17 2001-05-29 George Dimelow Alexander Lord Method of treating mammals
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
JPH10262694A (ja) 1997-03-28 1998-10-06 Sumitomo Forestry Co Ltd Ｂ細胞性リンパ腫の骨髄転移検査法
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
CN1287853C (zh) 1998-01-30 2006-12-06 拜奥根Idec马萨诸塞公司 用淋巴毒素(lt)途径抑制物治疗滤泡性淋巴瘤
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
KR20010075348A (ko) * 1998-09-25 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 아세틸디날린과 겜시타빈, 카페시타빈 또는 시스플라틴을함께 사용하는 항암 화학요법
CZ20011342A3 (cs) 1998-10-13 2001-09-12 Fujisawa Pharmaceutical Co., Ltd. Cyklické tetrapeptidy
EP1173562A2 (en) 1999-05-03 2002-01-23 Methylgene, Inc. Inhibition of histone deacetylase
US6450992B1 (en) 1999-07-02 2002-09-17 Smith & Nephew, Inc. Cannula interface
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
DE60143520D1 (de) 2000-03-24 2011-01-05 Methylgene Inc Inhibitoren der histon-deacetylase
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6533803B2 (en) * 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
EP2269609A3 (en) * 2001-10-16 2012-07-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
US20040018968A1 (en) * 2002-04-15 2004-01-29 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
ATE462426T1 (de) * 2003-08-26 2010-04-15 Merck Hdac Res Llc Verwendung von saha zur behandlung von mesotheliom
CN102349927A (zh) 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
EP1933825A2 (en) * 2005-08-18 2008-06-25 Merck and Co., Inc. Combination methods of saha and targretin for treating cancer
JP2009514891A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法
CA2626679C (en) 2005-11-04 2011-08-16 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
CN101299921A (zh) * 2005-11-04 2008-11-05 默克公司 用saha和硼替佐米治疗癌症的方法

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690918A (en) * 1985-01-30 1987-09-01 Teruhiko Beppu Use of trichostatin compounds for treating tumor cells
US5773474A (en) * 1988-11-14 1998-06-30 The Trustees Of Columbia University In The City Of New York And Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5932616A (en) * 1991-10-04 1999-08-03 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US6087367A (en) * 1991-10-04 2000-07-11 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5654333A (en) * 1991-10-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Methods for prevention of cancer using phenylacetic acids and derivatives thereof
US6239176B1 (en) * 1997-03-11 2001-05-29 Beacon Laboratories, Inc. Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6451334B2 (en) * 1997-05-30 2002-09-17 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US20040002506A1 (en) * 1999-09-08 2004-01-01 Sloan Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
US20030082666A1 (en) * 2000-11-21 2003-05-01 Kammer Gary M. Method of treating autoimmune diseases
US20030114525A1 (en) * 2000-11-21 2003-06-19 Kammer Gary M. Method of treating autoimmune diseases
US20040167184A1 (en) * 2001-03-27 2004-08-26 Wiech Norbert L. Treatment of lung cells with histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20030161830A1 (en) * 2001-06-14 2003-08-28 Jackson Donald G. Novel human histone deacetylases
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20040127523A1 (en) * 2002-03-04 2004-07-01 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040127522A1 (en) * 2002-03-04 2004-07-01 Chiao Judy H. Methods of treating cancer with HDAC inhibitors
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid
US20040087631A1 (en) * 2002-03-04 2004-05-06 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20060167103A1 (en) * 2002-03-04 2006-07-27 Aton Pharma, Inc. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20040266818A1 (en) * 2003-04-01 2004-12-30 Ronald Breslow Hydroxamic acid compounds and methods of use thereof

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879865B2 (en) 2001-10-16 2011-02-01 Sloan-Kettering Institute For Cancer Research Treatment of cancer of the brain using histone deacetylase inhibitors
US20110124731A1 (en) * 2001-10-16 2011-05-26 Sloan-Kettering Institute For Cancer Research Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors
US20060079551A1 (en) * 2001-10-16 2006-04-13 Richon Victoria M Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20060009526A1 (en) * 2002-02-15 2006-01-12 Richon Victoria M Method of treating TRX mediated diseases
US20060009527A1 (en) * 2002-02-15 2006-01-12 Richon Victoria M Method of treating TRX mediated diseases
US7375137B2 (en) 2002-03-04 2008-05-20 Merck Hdac Research, Llc Methods of treating cancer with HDAC inhibitors
US20080119562A1 (en) * 2002-03-04 2008-05-22 Richon Victoria M Methods of Inducing Terminal Differentiation
US7399787B2 (en) 2002-03-04 2008-07-15 Merck Hdac Research, Llc Methods of treating cancer with HDAC inhibitors
US20080228005A1 (en) * 2002-03-04 2008-09-18 Miller Thomas A Polymorphs of suberoylanilide hydroxamic acid
US20080249179A1 (en) * 2002-03-04 2008-10-09 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20100168242A1 (en) * 2002-03-04 2010-07-01 Miller Thomas A Polymorphs of suberoylanilide hydroxamic acid
US20040127522A1 (en) * 2002-03-04 2004-07-01 Chiao Judy H. Methods of treating cancer with HDAC inhibitors
US20040127523A1 (en) * 2002-03-04 2004-07-01 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7732490B2 (en) 2002-03-04 2010-06-08 Merck Hdac Research, Llc Methods of treating cancer
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7847122B2 (en) 2002-03-04 2010-12-07 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7851509B2 (en) 2002-03-04 2010-12-14 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20080114069A1 (en) * 2002-03-04 2008-05-15 Richon Victoria M Methods of inducing terminal differentiation
US20040087631A1 (en) * 2002-03-04 2004-05-06 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7652069B2 (en) 2002-03-04 2010-01-26 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040122101A1 (en) * 2002-03-04 2004-06-24 Miller Thomas A. Polymorphs of suberoylanilide hydroxamic acid
US8067472B2 (en) 2002-03-04 2011-11-29 Merck Hdac Research, Llc Methods of treating Hodgkin's and non-Hodgkin's lymphoma
US20100210729A1 (en) * 2002-03-04 2010-08-19 Richon Victoria M Methods of inducing terminal differentiation
US20080194692A1 (en) * 2002-03-04 2008-08-14 Miller Thomas A Polymorphs of suberoylanilide hydroxamic acid
US8101663B2 (en) 2002-03-04 2012-01-24 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040018968A1 (en) * 2002-04-15 2004-01-29 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US20050048847A1 (en) * 2002-08-27 2005-03-03 Guang-Rung Hsieh Electrical power jack
US20040254220A1 (en) * 2003-03-17 2004-12-16 Syrrx, Inc. Histone deacetylase inhibitors
US20050137232A1 (en) * 2003-03-17 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20090012175A1 (en) * 2003-08-26 2009-01-08 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
EP1833500A1 (en) * 2004-12-14 2007-09-19 Biorunx Co., Ltd Method to enhance the bone formation activity of bmp by runx2 acetylation
EP1833500A4 (en) * 2004-12-14 2009-08-12 Biorunx Co Ltd METHOD FOR REINFORCING BONE-MAKING ACTIVITY OF BMP BY RUNX2 ACETYLATION
US20060205941A1 (en) * 2004-12-16 2006-09-14 Bressi Jerome C Histone deacetylase inhibitors
US10799469B2 (en) 2005-02-03 2020-10-13 Topotarget Uk Limited Combination therapies using HDAC inhibitors
US10285959B2 (en) 2005-02-03 2019-05-14 Topotarget Uk Limited Combination therapies using HDAC inhibitors
US20080202944A1 (en) * 2005-04-22 2008-08-28 Eduardo Santoli Method for Use of an Electrochemical Sensor and Electrodes Forming Said Sensor
US20090215800A1 (en) * 2005-05-05 2009-08-27 Chroma Therapeutics Ltd Enzyme and Receptor Modulation
US20060258694A1 (en) * 2005-05-11 2006-11-16 Bressi Jerome C Histone deacetylase inhibitors
US9957227B2 (en) 2005-05-13 2018-05-01 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US20080194690A1 (en) * 2005-05-13 2008-08-14 Topotarget Uk Limited Pharmaceutical Formulations Of Hdac Inhibitors
US9856211B2 (en) 2005-05-13 2018-01-02 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US8835501B2 (en) 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US8288440B2 (en) 2005-05-20 2012-10-16 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20100119596A1 (en) * 2005-05-20 2010-05-13 Jeannie Chow Wong Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8450372B2 (en) 2005-05-20 2013-05-28 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8093295B2 (en) 2005-05-20 2012-01-10 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing the same
US20080132575A1 (en) * 2005-05-20 2008-06-05 Jeannie Chow Wong Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same
US20080119648A1 (en) * 2005-07-14 2008-05-22 Bressi Jerome C Histone deacetylase inhibitors
US20080108829A1 (en) * 2005-07-14 2008-05-08 Bressi Jerome C Histone deacetylase inhibitors
US20090111996A1 (en) * 2005-07-14 2009-04-30 Bressi Jerome C Histone deacetylase inhibitors
US20070015809A1 (en) * 2005-07-14 2007-01-18 Bressi Jerome C Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080114037A1 (en) * 2005-07-14 2008-05-15 Bressi Jerome C Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080119658A1 (en) * 2005-07-14 2008-05-22 Bressi Jerome C Histone deacetylase inhibitors
WO2007031853A3 (en) * 2005-09-14 2007-05-18 Hamlet Pharma Ab Therapeutic combination of hamlet and a hdac inhibitor to treat cancer
WO2007031853A2 (en) * 2005-09-14 2007-03-22 Nya Hamlet Pharma Ab Therapeutic combination of hamlet and a hdac inhibitor to treat cancer
US20090036368A1 (en) * 2005-09-14 2009-02-05 Hamlet Pharma Ab Therapeutic Combination
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
WO2007056244A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US20090247549A1 (en) * 2005-11-04 2009-10-01 Frankel Stanley R Methods of using saha and bortezomib for treating cancer
WO2007056244A3 (en) * 2005-11-04 2007-09-07 Merck & Co Inc Methods of using saha and erlotinib for treating cancer
US20080274120A1 (en) * 2005-11-10 2008-11-06 Topotarget Uk Limited Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
US9603926B2 (en) 2005-11-10 2017-03-28 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors for the treatment of cancer
US8828392B2 (en) 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
US20070173527A1 (en) * 2006-01-13 2007-07-26 Bressi Jerome C Histone deacetylase inhibitors
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US20090305956A1 (en) * 2006-04-24 2009-12-10 Gloucester Pharmaceuticals, Inc. Treatment of Ras-Expressing Tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US20080124403A1 (en) * 2006-06-08 2008-05-29 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
US20100317678A1 (en) * 2006-10-30 2010-12-16 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US20100113392A1 (en) * 2006-11-03 2010-05-06 Badros Ashraf Z Methods of using saha and bortezomib for treating multiple myeloma
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US20090186382A1 (en) * 2006-12-29 2009-07-23 Verdine Gregory L Preparation of Romidepsin
US20090209616A1 (en) * 2006-12-29 2009-08-20 Verdine Gregory L Preparation of romidepsin
US20100093610A1 (en) * 2006-12-29 2010-04-15 Vrolijk Nicholas H Romidepsin-based treatments for cancer
US20100113602A1 (en) * 2007-02-27 2010-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US20100286279A1 (en) * 2007-09-25 2010-11-11 Topotarget Uk Limited Methods of Synthesis of Certain Hydroxamic Acid Compounds
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
US20110003777A1 (en) * 2008-03-07 2011-01-06 Topotarget A/S Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat
US20100190694A1 (en) * 2009-01-14 2010-07-29 Jan Fagerberg Methods for identifying patients who will respond well to cancer treatment
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9624271B2 (en) 2010-07-12 2017-04-18 Celgene Corporation Romidepsin solid forms and uses thereof
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2011311531B2 (en) * 2010-10-08 2014-11-20 Life Sciences Research Partners Vzw HDAC inhibitors to treat Charcot-Marie-Tooth disease
US9238028B2 (en) * 2010-10-08 2016-01-19 Vib Vzw HDAC inhibitors to treat charcot-marie-tooth disease
WO2012045804A1 (en) * 2010-10-08 2012-04-12 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9782451B2 (en) 2013-12-27 2017-10-10 Celgene Corporation Romidepsin formulations and uses thereof
US9795650B2 (en) 2013-12-27 2017-10-24 Celgene Corporation Romidepsin formulations and uses thereof
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists

Also Published As

Publication number Publication date
CA2632078C (en) 2012-08-14
KR100868813B1 (ko) 2008-11-14
JP2010006822A (ja) 2010-01-14
JP4732693B2 (ja) 2011-07-27
US7399787B2 (en) 2008-07-15
CA2671976C (en) 2016-05-10
JP2014237669A (ja) 2014-12-18
US20080114069A1 (en) 2008-05-15
NO20044112L (no) 2004-11-30
CN1720034A (zh) 2006-01-11
RU2394022C2 (ru) 2010-07-10
CA2671976A1 (en) 2003-09-18
ES2532607T3 (es) 2015-03-30
WO2003075839A2 (en) 2003-09-18
RU2530648C2 (ru) 2014-10-10
CN103393630A (zh) 2013-11-20
RU2004133675A (ru) 2005-08-10
AU2003213684A1 (en) 2003-09-22
EP2082737A3 (en) 2009-08-12
IL197582A0 (en) 2009-12-24
EP1487426A2 (en) 2004-12-22
US20040127523A1 (en) 2004-07-01
NZ567758A (en) 2009-07-31
US20040127522A1 (en) 2004-07-01
US8067472B2 (en) 2011-11-29
NO20092714L (no) 2004-10-11
JP5586896B2 (ja) 2014-09-10
CA2478094A1 (en) 2003-09-18
BR0308250A (pt) 2005-01-11
EP1487426B1 (en) 2012-08-22
NZ535578A (en) 2008-03-28
IL163909A (en) 2010-12-30
US7732490B2 (en) 2010-06-08
ZA200407942B (en) 2006-05-31
NO332749B1 (no) 2013-01-07
NO329984B1 (no) 2011-01-31
US20080119562A1 (en) 2008-05-22
RU2010108448A (ru) 2011-09-20
IL197582A (en) 2014-05-28
PL372239A1 (en) 2005-07-11
EP1487426A4 (en) 2007-09-19
AU2003213684B2 (en) 2007-04-26
KR20070057794A (ko) 2007-06-07
US20120041067A1 (en) 2012-02-16
RU2320331C2 (ru) 2008-03-27
EP2266552A3 (en) 2011-03-02
KR20080041307A (ko) 2008-05-09
ZA200601757B (en) 2007-11-28
RU2007112879A (ru) 2008-10-20
WO2003075839A3 (en) 2003-12-31
JP5675071B2 (ja) 2015-02-25
EP2322160A1 (en) 2011-05-18
KR100892016B1 (ko) 2009-04-07
EP2082737B1 (en) 2014-12-31
IL163909A0 (en) 2005-12-18
JP2005525369A (ja) 2005-08-25
EP2082737A2 (en) 2009-07-29
EP2266552A2 (en) 2010-12-29
NZ550185A (en) 2008-10-31
AU2003213684C1 (en) 2008-10-23
CA2478094C (en) 2010-11-23
CA2632078A1 (en) 2003-09-18
MXPA04008577A (es) 2005-07-13
US20100210729A1 (en) 2010-08-19
JP2010001302A (ja) 2010-01-07
CN101259120B (zh) 2012-07-04
HK1072362A1 (en) 2005-08-26
CN101259120A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
US7732490B2 (en) Methods of treating cancer
US7375137B2 (en) Methods of treating cancer with HDAC inhibitors
US8101663B2 (en) Polymorphs of suberoylanilide hydroxamic acid
US20090012175A1 (en) Methods of treating cancer with HDAC inhibitors
Richon et al. Methods of treating Hodgkin's and non-Hodgkin's lymphoma
AU2007203525C1 (en) Methods of Inducing Terminal Differentiation
KR20050020760A (ko) 말단 분화의 유도 방법
NZ568678A (en) Methods of inducing terminal differentiation using suberoylanilide hydroxamic acid (SAHA)

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERCK HDAC RESEARCH, LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATON PHARMA, INC.;REEL/FRAME:018312/0647

Effective date: 20060828

AS Assignment

Owner name: ATON PHARMA, INC. (A SUBSIDIARY OF MERCK & CO., IN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHIAO, JUDY H.;MILLER, THOMAS A.;RICHON, VICTORIA M.;REEL/FRAME:018651/0928;SIGNING DATES FROM 20060809 TO 20060821

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RICHON, VICTORIA M.;KELLY, W. KEVIN;REEL/FRAME:018651/0990;SIGNING DATES FROM 20060809 TO 20061023

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SLOAN-KETTERING INSTITUTE FOR CANCER RES;REEL/FRAME:022451/0708

Effective date: 20090323

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SLOAN-KETTERING INSTITUTE FOR CANCER RES;REEL/FRAME:024851/0340

Effective date: 20090323